Analyst Yun Zhong of Wedbush maintained a Buy rating on Wave Life Sciences, retaining the price target of $15.00.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Yun Zhong has given his Buy rating due to a combination of factors related to Wave Life Sciences’ lead program WVE-006 and its regulatory outlook. The latest RestorAATion-2 data show consistent, exposure-related improvements in RNA editing alongside evidence that WVE-006 can restore normal, inflammation-driven control of AAT production, reinforcing both efficacy and safety.
He also views WVE-006’s monthly subcutaneous dosing and favorable tolerability in patients with underlying liver dysfunction as key competitive advantages versus DNA-editing approaches. In addition, he expects forthcoming data from higher-dose cohorts and mid-2026 FDA feedback to clarify a potential accelerated approval pathway, supporting his unchanged $15 price target and overall positive risk‑reward assessment for WVE.